AstraZeneca/Infinity’s Hsp90 Inhibitor Advances In GIST
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive PFS data in patients treated with retaspimycin presented at ASCO; Phase III to start in third quarter.
You may also be interested in...
Infinity Regains Rights To Its Lead Program
Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.
Infinity Regains Rights To Its Lead Program
Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.
AstraZeneca/Infinity’s Hsp90 Inhibitor Fails Phase II Prostate Cancer Study
Phase III study of IPI-504 in gastrointestinal cancer still on track for later this year.